The National Comprehensive Cancer Network (NCCN) recommends Oncotype DX as the preferred gene expression assay for predicting prognosis and chemotherapy benefit in N0/N1 postmenopausal, HR-positive, and HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.